HilleVax (HilleVax) EBIT per Share : $-3.23 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is HilleVax EBIT per Share?

HilleVax's EBIT per Share for the three months ended in Mar. 2024 was $-0.95. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.23.

During the past 3 years, the average EBIT per Share Growth Rate was -246.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for HilleVax's EBIT per Share or its related term are showing as below:

HLVX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -246.4 Med: -246.4 Max: -246.4
Current: -246.4

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of HilleVax was -246.40% per year. The lowest was -246.40% per year. And the median was -246.40% per year.

HLVX's 3-Year EBIT Growth Rate is ranked worse than
99.08% of 1311 companies
in the Biotechnology industry
Industry Median: 3.5 vs HLVX: -246.40

HilleVax's EBIT for the three months ended in Mar. 2024 was $-46.10 Mil.

HilleVax EBIT per Share Historical Data

The historical data trend for HilleVax's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax EBIT per Share Chart

HilleVax Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.13

-6.11

-5.76

-2.99

HilleVax Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial									-0.70	-0.72	-0.80	-0.76	-0.95

HilleVax EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

HilleVax's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-121.174	/	40.598
=	-2.98

HilleVax's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-46.102	/	48.460
=	-0.95

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.23

HilleVax (NAS:HLVX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

HilleVax EBIT per Share Related Terms

Thank you for viewing the detailed overview of HilleVax's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

HilleVax (HilleVax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 State Street, Suite 100 - No. 9995, Boston, MA, USA, 02109

Website

https://www.hillevax.com

HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Executives

Astrid Borkowski	officer: Chief Medical Officer	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Shane Maltbie	officer: Chief Financial Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Frazier Life Sciences X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Fhmls X, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin	director	C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda	director	C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc.	10 percent owner	75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu	director	ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Aditya Kohli	director, officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
David A Socks	officer: CFO & Chief Business Officer	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668